Q-omics provides the consensus-scored RGS9BP profile across patient tissues and cancer cell-line models. RGS9BP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RGS9BP is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RGS9BP RNA expression shows 16,409 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RGS9BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS9BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS9BP survival associations across molecular data types. RGS9BP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS9BP RNA expression–survival associations across cancer types. High RGS9BP expression shows unfavorable associations in ACC, UCEC, LIHC and SKCM, but favorable associations in HNSC and LAML. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RGS9BP RNA expression.
This table summarizes RGS9BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RGS9BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS9BP shows lower tumor expression in KIRC, THCA, LUAD, LUSC and STAD and higher tumor expression in LIHC. The KIRC box plot shows higher RGS9BP RNA expression in normal versus tumor tissue (log2 FC = −0.260, t-test p < 0.001).
This table shows molecular features associated with RGS9BP in patient tissues and cancer cell lines. In patient samples, RGS9BP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS9BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
